Print this page    •   Back to Web version of article

Tuberculosis Research & Development: A Critical Analysis

December 2006

TAG interviewed 100 institutions and documented the top 40 investors in TB R&D in 2005. Results highlighted in the report showed that new tools including diagnostics, drugs and vaccines received combined funding of $206 million in 2005 -- diagnostics, $16 million; drugs, $120 million; and vaccines, $70 million. At this rate, only $2 billion will be available over the next decade, whereas the Global Plan to Stop TB 2006-2015 estimates that $9 billion will be needed, revealing a new TB tools funding gap of $7 billion. Basic science and operational research received $94 million and $50 million, respectively, but there are no global targets with which to compare the investments in basic and operational research.

To improve upon decades old technology and match urgency with need, Treatment Action Group demands donors of TB R&D worldwide -- including G8 and developing countries -- increase their investment fivefold, from less than $400 million per year to $2 billion per year, with $1.05 billion directed towards new tools research and $950 million directed towards basic science, infrastructure development, and operational research each year, for a total of $20 billion in TB R&D over the coming decade.

Full report available at

Back to the TAGline December 2006 contents page.

This article was provided by Treatment Action Group. It is a part of the publication TAGline. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.